Holders — by stockHoldings — by fund
Sio Capital Management, LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001482416
$604.3M
disclosed book value
59
positions
9%
largest position share
Positions, as of 2026-06-30
top 59 of 59 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | AVRANTERIS TECHNOLOGIES GLOBAL | 5.5M | $54.6M | 9% |
| 2 | CORCENCORA INC | 173,588 | $49.1M | 8.1% |
| 3 | MMSMAXIMUS INC | 715,267 | $38.5M | 6.4% |
| 4 | ALLOALLOGENE THERAPEUTICS INC | 13.3M | $27.7M | 4.6% |
| 5 | GMEDGLOBUS MED INC | 301,816 | $23.8M | 3.9% |
| 6 | GSKGSK PLC | 436,700 | $22.9M | 3.8% |
| 7 | TYRATYRA BIOSCIENCES INC | 695,315 | $22.2M | 3.7% |
| 8 | WAYWAYSTAR HLDG CORP | 925,834 | $19.0M | 3.1% |
| 9 | SLSSELLAS LIFE SCIENCES GROUP IPUT | 1.2M | $18.2M | 3% |
| 10 | IDYAIDEAYA BIOSCIENCES INC | 480,383 | $17.9M | 3% |
| 11 | ORKAORUKA THERAPEUTICS INC | 177,118 | $16.9M | 2.8% |
| 12 | CITHE CIGNA GROUP | 57,750 | $15.9M | 2.6% |
| 13 | SNYSANOFI SA | 364,200 | $15.5M | 2.6% |
| 14 | ICON PUB LTD CO | 88,186 | $15.3M | 2.5% |
| 15 | VTRSVIATRIS INC | 954,299 | $15.2M | 2.5% |
| 16 | CROSS CTRY HEALTHCARE INC | 1.1M | $14.5M | 2.4% |
| 17 | RAPPRAPPORT THERAPEUTICS INC | 307,657 | $12.8M | 2.1% |
| 18 | ABTABBOTT LABORATORIES | 128,656 | $11.7M | 1.9% |
| 19 | CELCCELCUITY INC | 110,022 | $11.5M | 1.9% |
| 20 | ZBHZIMMER BIOMET HOLDINGS INC | 131,445 | $11.3M | 1.9% |
| 21 | REGNREGENERON PHARMACEUTICALS | 18,000 | $11.2M | 1.9% |
| 22 | BMYBRISTOL-MYERS SQUIBB CO | 193,500 | $11.1M | 1.8% |
| 23 | MEDTRONIC PLC | 142,500 | $11.1M | 1.8% |
| 24 | VIRVIR BIOTECHNOLOGY INC | 1.1M | $11.0M | 1.8% |
| 25 | SENSSENSEONICS HLDGS INC | 1.6M | $9.0M | 1.5% |
| 26 | EYPTEYEPOINT INC | 623,130 | $8.9M | 1.5% |
| 27 | HELPCYBIN INC | 1.3M | $8.6M | 1.4% |
| 28 | ANIPANI PHARMACEUTICALS INC | 97,305 | $8.1M | 1.3% |
| 29 | TARAPROTARA THERAPEUTICS INC | 1.9M | $7.3M | 1.2% |
| 30 | RLMDRELMADA THERAPEUTICS INC | 1.0M | $6.9M | 1.1% |
| 31 | TNGXTANGO THERAPEUTICS INC | 208,500 | $6.5M | 1.1% |
| 32 | AQSTAQUESTIVE THERAPEUTICS INC | 1.5M | $6.2M | 1% |
| 33 | DNTHDIANTHUS THERAPEUTICS INC | 59,254 | $5.8M | 1% |
| 34 | SIONSIONNA THERAPEUTICS INC | 127,808 | $5.6M | 0.9% |
| 35 | OCULOCULAR THERAPEUTIX INC | 539,493 | $5.3M | 0.9% |
| 36 | ZBIOZENAS BIOPHARMA INC | 208,557 | $5.3M | 0.9% |
| 37 | DRUGBRIGHT MINDS BIOSCIENCES INC | 73,952 | $5.2M | 0.9% |
| 38 | OKURONKURE THERAPEUTICS INC | 1.1M | $4.9M | 0.8% |
| 39 | SVRASAVARA INC | 617,675 | $3.8M | 0.6% |
| 40 | PMVPPMV PHARMACEUTICALS INC | 2.6M | $3.5M | 0.6% |
| 41 | AVAHAVEANNA HEALTHCARE HLDGS INC | 369,036 | $3.2M | 0.5% |
| 42 | OVIDOVID THERAPEUTICS INC | 1.0M | $2.7M | 0.4% |
| 43 | IMNMIMMUNOME INC | 124,168 | $2.6M | 0.4% |
| 44 | HIMSHIMS & HERS HEALTH INCCALL | 75,000 | $2.6M | 0.4% |
| 45 | ANTXAN2 THERAPEUTICS INC | 529,933 | $2.6M | 0.4% |
| 46 | SERSERINA THERAPEUTICS INC | 1.0M | $1.9M | 0.3% |
| 47 | ALGSALIGOS THERAPEUTICS INC | 327,237 | $1.9M | 0.3% |
| 48 | IBIOIBIO INC | 904,268 | $1.6M | 0.3% |
| 49 | XLOXILIO THERAPEUTICS INC | 152,464 | $1.5M | 0.2% |
| 50 | AORTARTIVION INC | 48,481 | $1.1M | 0.2% |
| 51 | BBOTBRIDGEBIO ONCOLOGY THERAPEUT | 130,628 | $995,385 | 0.2% |
| 52 | TELATELA BIO INC | 636,300 | $477,225 | 0.1% |
| 53 | ADGMADAGIO MED HLDGS INC | 698,989 | $455,461 | 0.1% |
| 54 | NMTCNEUROONE MED TECHNOLOGIES CO | 82,767 | $251,612 | 0% |
| 55 | ENVBENVERIC BIOSCIENCES INC | 180,000 | $248,400 | 0% |
| 56 | MODDMODULAR MED INC | 26,190 | $117,855 | 0% |
| 57 | QTIQT IMAGING HLDGS INC | 15,236 | $62,011 | 0% |
| 58 | RCKTWROCKET PHARMACEUTICALS INC | 400,000 | $1,480 | 0% |
| 59 | HUMAWHUMACYTE INC | 49,998 | $477 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.